Directed Therapy of Subtypes of Triple-Negative Breast Cancer
Directed Therapy of Subtypes of Triple-Negative Breast Cancer
复制标题
DOI：
10.1634/theoncologist.2010-s5-49
复制
发表时间：
2010-11-01
期刊：
影响因子：
5.8
通讯作者：
Carey, Lisa A.
中科院分区：
文献类型：
--
作者：
Carey, Lisa A.
在发达国家，乳腺癌的死亡率已有显著改善，但几乎所有这些益处都出现在雌激素受体（ER）阳性和人表皮生长因子受体（HER）-2阳性的亚群中。三阴性乳腺癌定义为雌激素受体、孕激素受体和HER - 2均为阴性的肿瘤，占乳腺癌的少数。然而，由于这种特殊亚型预后不良，三阴性疾病在转移性病例和乳腺癌死亡病例中所占比例过高。虽然化疗对三阴性疾病有效，但研究仍在继续以更好地靶向治疗并预测预后。近期研究表明BRCA突变与三阴性疾病之间存在联系，但这种联系的本质仍不明确。抗血管生成药物如贝伐珠单抗已在各亚型中显示出疗效。最近，聚（ADP - 核糖）聚合酶抑制剂似乎利用了合成致死性（或双通路抑制）的概念来攻击三阴性和与BRCA相关的肿瘤。这些以及其他关于三阴性疾病的研究将有助于我们更好地确定有效的治疗方案并改善这些患者的预后。本文探讨了三阴性乳腺癌的性质及治疗策略。《肿瘤学家》2010年；15（增刊5）：49 - 56
In developed countries, there has been a remarkable improvement in mortality from breast cancer, but almost all of that benefit has occurred in the estrogen receptor (ER)(+) and human epidermal growth factor receptor (HER)-2(+) subsets. Triple-negative breast cancer, defined as tumors that are negative for ER, progesterone receptor, and HER-2, represent a minority of breast cancers. However, because of the poor prognosis in this particular subtype, triple-negative disease accounts for a disproportionate number of metastatic cases and breast cancer deaths. While chemotherapy is effective in triple-negative disease, research continues to better target therapies and predict prognosis. Recent studies have suggested a link between BRCA mutations and triple-negative disease, but the nature of this link remains opaque. Antiangiogenic agents such as bevacizumab have demonstrated efficacy across subtypes. More recently, poly(ADP-ribose) polymerase inhibitors appear to take advantage of the concept of synthetic lethality, or dual pathway inhibition, in attacking triple-negative and BRCA-associated tumors. These and other studies in triple-negative disease will help us to better identify effective treatment options and improve outcomes in these patients. This article addresses the nature of, and therapeutic strategies for, triple-negative breast cancer. The Oncologist 2010; 15(suppl 5):49-56